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See related article in EMBO Molecular Medicine http://dx.doi.org/10.1002/emmm.201100205Semaphorins (SEMAs) are a superfamily
of secreted or membrane-associatedglycoproteins implicated in the control
of axonal wiring and involved in angio-
genesis and cancer progression. Class-3
SEMAs are the only secreted vertebrate
SEMAs and several of them are regulated
by protease-mediated cleavage (Cappar-
uccia & Tamagnone, 2009). Their high-
affinity receptors, Plexins and co-recep-
tor Neuropilins, are expressed in a wide
variety of cell types including endothelial
and tumour cells. Plexins show an
intrinsic R-Ras GAP activity, but inter-
estingly also form complexes with
additional transmembrane molecules,
including certain receptor tyrosine
kinases (RTKs) such as c-Met, ErbB2
and vascular endothelial growth factor
receptor 2 (VEGFR2), that are transacti-
vated by Plexins and initiate critical
signalling pathways. These functional
interactions with transactivated kinase
receptors are key to define the cellular
activities of SEMAs and convert the
SEMAs into pleiotropic molecules. Thus,
SEMAs can positively or negatively
modulate many intrinsic properties of
tumour cells, such as proliferation, cell
survival, alteration in cell adhesion and
tumour invasiveness, but also modulateTumor Angiogenesis Group, Catalan Institute of
Oncology – IDIBELL, L’Hospitalet de Llobregat,
Spain




 2012 EMBO Molecular Medicineseveral stromal components including
endothelial cell migration and survival
(Capparuccia & Tamagnone, 2009; Serini
et al, 2009).
Sema3E is one of the SEMAs impli-
cated in tumour invasion and metasta-
tization and its expression correlates
with the metastatic process. Sema3E is
synthesized as a full-length precursor
molecule and its proteolytic maturation
by Furin proprotein-convertase produces
the active fragment p61-Sema3E, which
is required and sufficient for the function
of Sema3E in tumour invasiveness
and metastasis (Casazza et al, 2010).
Furthermore, Sema3E exerts pleiotropic
activities through its specific receptor,
Plexin-D1 (PlxnD1), including a collaps-
ing pro-apoptotic response in endothelial
cells and a pro-invasive and pro-
metastatic effect on tumour cells. This
leads to a paradoxical dual effect where
the overexpression of Sema3E on one
hand reduces the tumour burden by
counteracting tumour angiogenesis, but
on the other increases the metastatic
spread of the tumour. The dual activities
of p61-Sema3E depend on the specific
transactivatedmolecules recruited by the
complex Sema3E–PlxnD1 in the different
types of cells. In endothelial cells,
the intrinsic R-Ras GAP activity of
PlxnD1 promotes a cell-collapsing
response as well as an Arf6 GTPase-
mediated integrin-beta1 endocytosis and
decreased cellular adhesion to the extra-
cellular matrix (Casazza et al, 2010;
Sakurai et al, 2010). In tumour cells,
on the contrary, ErbB2 plays a master
role in the pro-invasive, pro-metastaticEMBO Mol Med 4, 168–170properties of p61-Sema3E with
PlxnD1 forming a complex with ErbB2
that results in its transactivation
and further activation of EGFR-ErbB2-
mediated signalling pathways (Casazza
et al, 2010; Fig 1A). Thus, the well-
documented negative effect on endothe-
lial cells exerted by Sema3E makes it a
good candidate to block angiogenesis in
tumours. However, the heightened
tumour aggressiveness induced by this
pleiotropic molecule precludes its
possible exploitation as a therapeutic
molecule.
In this issue of EMBO Molecular
Medicine, Casazza et al deeply explore
the pleiotropic dual activities associated
to Sema3E. They identify a point-mutated
uncleavable Sema3E isoform (Uncl-
Sema3E) that selectively competes with
p61-Sema3E for the binding to PlxnD1
(Casazza et al, 2012). This molecule
retains the same anti-angiogenic activity,
but also exerts an unexpected anti-
invasive and anti-metastatic effect on
the tumour (Fig 1B). Similar to the
endogenous p61-Sema3E isoform, Uncl-
Sema3E binds to PlxnD1 in endothelial
cells and induces the expected SEMA-
driven anti-angiogenic collapsing response.
On the contrary, in tumour cells, the
Uncl-Sema3E–PlxnD1 complex fails to
elicit the ErbB2-mediated pro-invasive
and pro-metastatic pathway. Molecu-
larly, Casazza et al demonstrate that
Uncl-Sema3E not only interferes with the
endogenous Sema3E signalling, but is
also unable to induce the association of
PlxnD1 with ErbB2 in the tumour cell
context.www.embomolmed.org
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Figure 1. The multi-target effects of p61-Sema3E and uncleavable Sema3E (Uncl-Sema3E) in tumours.
A. Endogenous Sema3E is converted by Furin-mediated cleavage in the active p61-Sema3E. In endothelial cells, its binding to PlxnD1 triggers the intrinsic R-Ras
GAP activity of PlxnD1 and results in an anti-angiogenic effect due to the pro-apoptotic collapsing response and disassembly of focal adhesions. In tumour cells,
binding of p61-Sema3E to PlxnD1 promotes the formation of a heteromultimeric complex with ErbB2 RTK that leads to its transactivation and further
activation of ErbB2-EGFR-mediated pro-invasive and pro-metastatic signalling pathway.
B. Uncl-Sema3E effectively competes with p61-Sema3E for the binding to PlxnD1. Upon binding, it induces PlxnD1 activation and triggers the same signalling
molecules and anti-angiogenic effect on endothelial cells. On the contrary, in tumour cells, Uncl-Sema3E binding to PlxnD1 is unable to form a complex and
activate the ErbB2-EGFR response, therefore, producing a anti-invasive and anti-metastatic effect.
» The study from Casazza
et al points out a remarkable
pleiotropic anti-cancer
potential of Uncl-Sema3E




and invasion/metastasis. «The study from Casazza et al points
out a remarkable pleiotropic anti-cancer
potential of Uncl-Sema3E but also reveals
several relevant therapeutic opportu-
nities dually targeting angiogenesis and
invasion/metastasis. On the one hand,
based on the observation that the
uncleavable molecule demonstrates a
dominant-negative function over the
endogenous Sema3E signalling, one spe-
cific therapeutic approach could be the
use of a recombinant Uncl-Sema3E as a
drug that would maintain the known
anti-angiogenic activity of Sema3E
without activating the pro-invasive and
pro-metastatic process. Interestingly,
the receptor PlxnD1 is generally lowwww.embomolmed.orgexpressed in normal adult tissue but it is
elevated in tumour vessels (endothelial
cells) and in tumour cells (Roodink et al,
2009). Thus, with this tumour-restricted
expression pattern one would expect to
find lower toxicities of this recombinant
drug, but this has to be experimentally
determined.
Another specific therapeutic opportu-
nity arising from the study is the devel-
opment of new drugs blocking the
convertase Furin that is responsible for
the proteolytic cleavage of the full-length
Sema3E into p61-Sema3E. By inhibiting
Furin the endogenous full-length Sema3E
would not be effectively cleaved, and
an uncleaved form would accumulate in
Sema3E-expressing tumours. Uncleaved
Sema3E accumulation by Furin inhibi-
tion would lead to the competitive
blockage of p61-Sema3E pro-invasive
and pro-metastatic activity without
impairing the anti-angiogenic effects of
cleaved Sema3E. To further support
this possibility, Furin is frequently
expressed in human cancers and its
expression correlates with aggressive-
ness and metastasis, thus making it a
potential target for anti-cancer therapies
(Christensen et al, 2005).EMBO Mol Med 4, 168–170A crucial point in the putative applic-
ability of Sema3E-related therapies is
the critical functional link between
Sema3E–PlxnD1 and its transactivated
associated molecules. The repertoire of
transactivated receptor tyrosin-kinases
expressed in the cells (among them
c-Met, ErbBs and VEGFR2) could indeed
provoke variability in the cell responses
to Sema3E-related therapies, limiting
their effects to a specific cancer or more
importantly resulting in opposite out-
come in the different tumour types.
Therefore, it would be critical to profile
the specific repertoire of transactivated
molecules and how they interact with
the Sema3E–PlxnD1 complex in order to
anticipate the consequences of recombi-
nant Uncl-Sema3E treatment or Furin
cleavage inhibition.
In the context of other anti-tumour
therapies, the article from Casazza et al
further emphasizes the need of a careful
reflection on the use of anti-angiogenic
therapy in the treatment of cancer.
In a variety of experimental systems,
several previous studies have indeed
pointed out an unexpected side effect of
anti-angiogenic treatments promoting
tumour agressiveness (Casazza et al, 2012 EMBO Molecular Medicine 169
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1702010; Ebos & Kerbel, 2011; Paez-Ribes
et al, 2009). Sema3E as well as VEGF/R
inhibitors increase tumour invasiveness
but while for Sema3E this effect is
achieved by the activation of specific
pathways in tumour cells, the maligniza-
tion induced by anti-VEGF therapy is
associated with vascular trimming and
tumour hypoxia. Due to the implication
of different mechanisms involved in
the spread of tumour cells promoted
by these two distinct treatments, the
inhibition of pro-invasive and pro-
metastatic process by Uncl-Sema3E
strongly supports a possible added
therapeutic potential of this molecule in
anti-VEGF/R treated tumours. Indeed,
results from Casazza et al demonstrate
Uncl-Sema3E anti-tumour activity is
maintained in models refractory to VEGF
therapy. Thus, further efforts have to be
made to define the anti-cancer outcome
of combinatorial Uncl-Sema3E together
with standard anti-angiogenic therapy
to determine whether there could
be additive anti-angiogenic effects and
compensatory anti-invasive and anti-
metastatic effects. 2012 EMBO Molecular MedicineAcknowledgements
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